[Bexarotene: targretin].
Beylot-Barry
M
M
Service de Dermatologie, Hôpital Haut-Lévêque, CHU de Bordeaux et EA 2406, Université Victor Segalen, Bordeaux 2. marie.beylot-barry@chu-bordeaux.fr
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077610:Bexarotene; D006801:Humans; D012878:Skin Neoplasms / Q000188:drug therapy*; D013764:Tetrahydronaphthalenes / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene